Chu Dijon Bourgogne
Dijon, 21000, France
Location status: Recruiting
NCT Number: NCT06138925
Cerebral palsy (CP) is currently one of the major causes of disability in children. The presence of various disorders (muscle stiffness, architectural bone defects, spasticity) leads to a number of functional impacts, including severe impairment of mobility, particularly locomotion. Locomotion can be assessed using a motion capture system that enables 3-dimensional analysis, in order to help make treatment decisions and quantify them. Although these systems are currently considered to be the gold standard, the fact remains that they cause a certain amount of patient fatigue (long set-up times) and that walking is assessed in a laboratory rather than in real life.
Today, technological advances have brought to the fore other gait analysis devices, such as inertial measurement units (IMUs). Various systems incorporating IMUs in the feet, for example, respond to these problems of analysing walking in real-life situations. The IMUs record the movements and orientation of the foot in space; the data is then processed by algorithms to recognise walking steps and calculate the spatio-temporal parameters of locomotion. Additional IMUs positioned on the body can be grafted onto this system to provide a more precise analysis of locomotion, in particular by calculating the movements of the various joints of the lower limb. However, before such devices can be used in a pathological paediatric population, they must be validated in a healthy population. This validation must be conducted using a precise method that has been widely documented in the COSMIN recommendations (Consensus-based Standards for the selection of health Measurement Instruments). The first stage will assess the safety of the IMU devices in a healthy paediatric population, and the validity of the spatio-temporal parameters. If these properties are deemed to be compliant, these same parameters will be assessed in a paediatric population with cerebral palsy in the second stage.
Interested in participating?
Request Info7 year–17 year
All sexes
Interventional
Not applicable
Dijon, 21000, France
Location status: Recruiting
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
PATIENT GROUP (IN ADDITION TO THOSE ABOVE)
Exclusion criteria
3-dimensional gait analysis with inertial measurement units (IMUs) on flat ground at different speeds (slow, comfortable and fast)
analysis of running on flat ground at different speeds (comfortable and fast)
Time frame: During the study visit
participants' walking speed measured jointly by an IMU system in the shoe and a 3D locomotion analysis system
Contact information is provided by the study sponsor or research team.
Centre Hospitalier Universitaire Dijon
Other
Acronym: KAPP-IMU anc
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01829724
Brain Damage, Chronic, Brain Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT06769178
Brain Damage, Chronic, Brain Diseases
Istanbul, Ataşehir, Turkey (Türkiye)
View Trial DetailsNCT07730086
Brain Damage, Chronic, Brain Diseases
Minya, Menia Governorate, Egypt
View Trial DetailsNCT07715006
Brain Damage, Chronic, Brain Diseases
Pittsburgh, Pennsylvania, United States
View Trial Details